Compliance of patients with atrial fibrillation using new oral
anticoagulants - results survey

J 2024

Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey

BÚŘILOVÁ, Petra, Jiří BÚŘIL, Michal HARŠÁNY, Kamila DUFKOVÁ, Marta ŠENKYŘÍKOVÁ et. al.

Základní údaje

Originální název

Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey

Autoři

BÚŘILOVÁ, Petra (203 Česká republika, domácí), Jiří BÚŘIL (203 Česká republika, domácí), Michal HARŠÁNY (703 Slovensko, domácí), Kamila DUFKOVÁ (203 Česká republika, domácí), Marta ŠENKYŘÍKOVÁ (203 Česká republika, domácí), Dana DOLANOVÁ (703 Slovensko, domácí), Milos TABORSKY (203 Česká republika) a Andrea POKORNÁ (203 Česká republika, domácí)

Vydání

Cor et Vasa, PRAGUE, CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERY, 2024, 0010-8650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.200 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.33678/cor.2023.095

UT WoS

001184839300015

Klíčová slova anglicky

Atrial fi brillation; Compliance; New oral anticoagulants; Risk; Stroke

Štítky

14110127, 14110525, 14110611, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 4. 2024 08:42, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Continuous medication use is essential for patients with atrial fi brillation using new oral anticoagulants. Older age and polymorbidity may affect compliance related to the anticoagulation therapy. Methods: An observational cohort study (STROBE) assessed patients' compliance with selected cardiovascular diagnoses and other comorbidities who received NOAC and outpatient care in specialized clinics in the Czech Republic in the questionnaire survey between April and May 2023. Results: Patients meeting the study criteria were approached by the treating physician for inclusion (4 cardiology and 1 neurology clinic). A total of 274 patients (146 women, 128 men) with a primary diagnosis of atrial fibrillation and at least one confirmed secondary diagnosis of heart attack, cerebral infarction, transient cerebral ischemic attack (TIA), obesity, arterial hypertension, or diabetes mellitus participated. Statistical analysis confi rmed that patients with a history of stroke or TIA had a higher number of regular follow-up visits (once every three months) (p = 0.002492). Furthermore, data analysis demonstrated that patients who had been on treatment for a shorter time tended to have more frequent regular follow-up visits (treatment duration up to 3 months/average check-ups 1.7 times; 3-5 months/0.9 times; 6-12 months/0.7 times). In one patient (55 years) with paroxysmal atrial fibrillation and a diagnosis of TIA, who declared irregularity of NOAC use for 3-5 months of treatment, a relapse of TIA was identifi ed. Conclusion: A high burden of additional comorbidities was identifi ed in the observed sample, along with the inadequate declaration of the regularity of NOAC medication use and the resulting risks. Appropriate patient education is essential, especially among older patients at a high risk of stroke, considering the increasing prescription rates.

Návaznosti

MUNI/A/1560/2023, interní kód MU

Název: Komprehensivní přístup k hodnocení kvality ošetřovatelské péče

Investor: Masarykova univerzita, Komprehensivní přístup k hodnocení kvality ošetřovatelské péče

Citovat

BÚŘILOVÁ, Petra, Jiří BÚŘIL, Michal HARŠÁNY, Kamila DUFKOVÁ, Marta ŠENKYŘÍKOVÁ, Dana DOLANOVÁ, Milos TABORSKY a Andrea POKORNÁ. Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey. Cor et Vasa. PRAGUE: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERY, 2024, roč. 66, č. 1, s. 23-28. ISSN 0010-8650. Dostupné z: https://dx.doi.org/10.33678/cor.2023.095.

@article{2398217,
   author = {Búřilová, Petra and Búřil, Jiří and Haršány, Michal and Dufková, Kamila and Šenkyříková, Marta and Dolanová, Dana and Taborsky, Milos and Pokorná, Andrea},
   article_location = {PRAGUE},
   article_number = {1},
   doi = {http://dx.doi.org/10.33678/cor.2023.095},
   keywords = {Atrial fi brillation; Compliance; New oral anticoagulants; Risk; Stroke},
   language = {eng},
   issn = {0010-8650},
   journal = {Cor et Vasa},
   title = {Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey},
   url = {https://e-coretvasa.cz/artkey/cor-202401-0004_compliance-of-patients-with-atrial-fibrillation-using-new-oral-anticoagulants-results-survey.php},
   volume = {66},
   year = {2024}
}

TY  - JOUR
ID  - 2398217
AU  - Búřilová, Petra - Búřil, Jiří - Haršány, Michal - Dufková, Kamila - Šenkyříková, Marta - Dolanová, Dana - Taborsky, Milos - Pokorná, Andrea
PY  - 2024
TI  - Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey
JF  - Cor et Vasa
VL  - 66
IS  - 1
SP  - 23-28
EP  - 23-28
PB  - CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERY
SN  - 00108650
KW  - Atrial fi brillation
KW  - Compliance
KW  - New oral anticoagulants
KW  - Risk
KW  - Stroke
UR  - https://e-coretvasa.cz/artkey/cor-202401-0004_compliance-of-patients-with-atrial-fibrillation-using-new-oral-anticoagulants-results-survey.php
N2  - Introduction: Continuous medication use is essential for patients with atrial fi brillation using new oral anticoagulants. Older age and polymorbidity may affect compliance related to the anticoagulation therapy. Methods: An observational cohort study (STROBE) assessed patients' compliance with selected cardiovascular diagnoses and other comorbidities who received NOAC and outpatient care in specialized clinics in the Czech Republic in the questionnaire survey between April and May 2023. Results: Patients meeting the study criteria were approached by the treating physician for inclusion (4 cardiology and 1 neurology clinic). A total of 274 patients (146 women, 128 men) with a primary diagnosis of atrial fibrillation and at least one confirmed secondary diagnosis of heart attack, cerebral infarction, transient cerebral ischemic attack (TIA), obesity, arterial hypertension, or diabetes mellitus participated. Statistical analysis confi rmed that patients with a history of stroke or TIA had a higher number of regular follow-up visits (once every three months) (p = 0.002492). Furthermore, data analysis demonstrated that patients who had been on treatment for a shorter time tended to have more frequent regular follow-up visits (treatment duration up to 3 months/average check-ups 1.7 times; 3-5 months/0.9 times; 6-12 months/0.7 times). In one patient (55 years) with paroxysmal atrial fibrillation and a diagnosis of TIA, who declared irregularity of NOAC use for 3-5 months of treatment, a relapse of TIA was identifi ed. Conclusion: A high burden of additional comorbidities was identifi ed in the observed sample, along with the inadequate declaration of the regularity of NOAC medication use and the resulting risks. Appropriate patient education is essential, especially among older patients at a high risk of stroke, considering the increasing prescription rates.
ER  -

BÚŘILOVÁ, Petra, Jiří BÚŘIL, Michal HARŠÁNY, Kamila DUFKOVÁ, Marta ŠENKYŘÍKOVÁ, Dana DOLANOVÁ, Milos TABORSKY a Andrea POKORNÁ. Compliance of patients with atrial fibrillation using new oral anticoagulants - results survey. \textit{Cor et Vasa}. PRAGUE: CZECH SOC CARDIOLOGY \&{}amp; CZECH SOC CARDIOVASCULAR SURGERY, 2024, roč.~66, č.~1, s.~23-28. ISSN~0010-8650. Dostupné z: https://dx.doi.org/10.33678/cor.2023.095.

Podrobný výpis o publikaci